Pharnext
Manufacturing · France · 11-50 Employees
View Company Info for Free
Overview
Headquarters
46 Rue Saint-lazare, Paris, Ile-de-Franc...Phone Number
+33 141092230Website
www.pharnext.comRevenue
<$5 MillionStock Symbol
ALPHAIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Pharnext
Pharnext SA, a clinical-stage biopharmaceutical company, develops therapies for orphan and common neurodegenerative diseases in France. The company's products include SYNGILITY that has completed Phase III trial for the treatment of Charcot-Marie-Tooth disease type 1A; and PXT864, which has completed Phase II clinical trial to treat Alzheimer's disease, as well as Parkinson's disease and amyotrophic lateral sclerosis. It also develops PLEOTHERAPY, a big genetic data and artificial intelligence platform. Pharnext SA has an agreement with the University Hospital Institute Mediterranee Infection to evaluate repurposed drugs for potential use against the COVID-19 virus. The company was founded in 2007 and is headquartered in Issy-Les-Moulineaux, France.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Pharnext your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Pharnext is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Pharnext recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Pharnext
Click to see if Pharnext had a recent Job posting/layoffs
Product Launch: Get notified when Pharnext launches new products
Check if Pharnext has recently received funding, and reach out quickly before it becomes old news!
Pharnext, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Pharnext has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
Pharnext is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Pharnext is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Pharnext.
Pharnext financials insights
Gather financial insights about Pharnext, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Share Placement
$8.6M
2021
Share Placement
$9.3M
2022
Other Financing Round
$20.7M
Pharnext Tech Stack
A closer look at the technologies used by Pharnext
See more technologies
Most Recent Scoops
New Hire
Executive Move
Left Company
Executive Move
Left Company
Executive Move
Left Company
Executive Move
Pharnext has announced that David Solomon, Chief Executive Officer & Director of the Company, has left the organization.
Lateral Move
Executive Move
Pharnext News & Media
PHARNEXT : Pharnext unveils the latest progress of the PREMIER trial, pivotal Phase III clinical trial of PXT3003 in Charcot-Marie-Tooth disease type 1A
Full and original release on www.actusnews.com. Subscribe to this company's information.The Board of Directors of Pharnext Acknowledges the Resignation of Dr. David Horn SOLOMON from his Duties as Chief Executive Officer and Director of the Company
Pharnext SA (FR001400BV89 - ALPHA) (the "Company"), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, today announces the resignation of Dr. David Horn SOLOMON from his duties as Chief Executive Officer and Director of the Company.Completion of the Reverse Split of Its Shares on the Basis of 1 New Share for 5,000 Old Shares, Start of Trading of the Shares Resulting From the Reverse Split, and Capital Reductions
Pharnext SA (FR001400BV89 - ALPHA) (the "Company"), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, today announces the completion of the reverse stock split, as decided by its Board of Directors on September 26, 2022, on the basis of 1 new share with a par value of 1 euro for 5,000 old shares with a par value of 0.0002 euro, as authorized by the
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Pharnext
Sign Up For FreeTo access detailed company insights
Pharnext SA, a clinical-stage biopharmaceutical company, develops therapies for orphan and common neurodegenerative diseases in France. The company's products include SYNGILITY that has completed Phase III trial for the treatment of Charcot-Marie-Tooth disease type 1A; and PXT864, which has completed Phase II clinical trial to treat Alzheimer's dis... Read More
